SG Americas Securities
CATX icon

SG Americas Securities’s Perspective Therapeutics CATX Stock Holding History

SG Americas Securities’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,538
Closed -$46K – 3616
2025
Q3 		$46K Buy
+13,538
New +$49.4K ﹤0.01% 3210
2025
Q2 		– Sell
-20,789
Closed -$44K – 2997
2025
Q1 		$44K Sell
20,789
-5,299
-20% -$15.9K ﹤0.01% 3264
2024
Q4 		$83K Buy
26,088
+7,627
+41% +$62.3K ﹤0.01% 2792
2024
Q3 		$246K Buy
+18,461
New +$246K ﹤0.01% 2317

Other funds holding CATX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SG Americas Securities's CATX Position: Q4 2025 in Review

SG Americas Securities sold out of Perspective Therapeutics (CATX) in Q4 2025, closing a stake of 13,538 shares — an estimated $46K sold.

SG Americas Securities first reported a position in CATX in Q3 2024 and held it in 4 quarters. The position peaked at $246K in Q3 2024. 117 funds tracked by Wall St. Rank hold CATX as of Q4 2025.

  • SG Americas Securities reported no remaining Perspective Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SG Americas Securities sold 13,538 Perspective Therapeutics shares in Q4 2025, an estimated $46K.
  • SG Americas Securities first reported a position in Perspective Therapeutics in Q3 2024 and held it in 4 quarters.
  • SG Americas Securities's Perspective Therapeutics position peaked at $246K in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2025.

Based on SG Americas Securities's 13F filing for Q4 2025, filed 9 Jan 2026.